How many Trametinib clinical trials are there?

243 Trametinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 40 are actively recruiting participants. 81 are marked completed.

Are Trametinib clinical trials recruiting in 2026?

Yes — 40 Trametinib trials are actively recruiting in 2026, with 519 U.S. sites across 45 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Trametinib being studied for?

Trametinib is being studied for Melanoma, Cancer, Metastatic Melanoma, Colorectal Cancer, Unresectable Melanoma and 537 more. The trials are grouped by indication on this page.

What phase is Trametinib in?

Trametinib clinical trials span 4 Phase 4, 10 Phase 3, 108 Phase 2, 64 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Trametinib clinical trials?

The lead sponsor across the most Trametinib trials is Novartis Pharmaceuticals, with 117 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Trametinib Clinical Trials (2026): 243 Studies for Melanoma & Cancer

Creator: Hipa.ai Research
Published: 2026-05-29T17:20:39.570Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

243 Trametinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 135 indications (including Melanoma & Cancer) and 35,775 total planned enrollment. 10 Phase 3 Trametinib trials and 108 Phase 2, 4 Phase 4 are listed. 47 Trametinib clinical trials are actively recruiting at 519 U.S. sites across 45 states. Most recent activity: NCT06582745 (Dec 2039).

Where to Participate: All Trametinib Trial Sites in the U.S. (519 sites across 45 states)

Every actively recruiting Trametinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	UAB Comprehensive Cancer Center	Birmingham35249	NCT05372354	Map
AL	University of Alabama at Birmingham	Birmingham35233	NCT07110246	Map
AL	University of Alabama at Birmingham Comprehensive Cancer Center	Birmingham35294	NCT02693535	Map
AL	University of Alabama at Birmingham, Children's of Alabama	Birmingham35233	NCT04485559	Map
AK	Alaska Breast Care and Surgery LLC	Anchorage99508	NCT06475989	Map
AK	Alaska Oncology and Hematology LLC	Anchorage99508	NCT06475989	Map
AK	Alaska Women's Cancer Care	Anchorage99508	NCT06475989	Map
AK	Anchorage Associates in Radiation Medicine	Anchorage98508	NCT06475989	Map
AK	Katmai Oncology Group	Anchorage99508	NCT06475989	Map
AK	Providence Alaska Medical Center	Anchorage99508	NCT06475989	Map
AZ	Cancer Treatment Centers of America-Phoenix	Phoenix85338	NCT02693535	Map
AZ	Phoenix Children's Hospital	Phoenix85016	NCT05849662	Map
AZ	Honor Health Research Institute	Scottsdale85258	NCT03340506	Map
AR	Mercy Hospital Fort Smith	Fort Smith72903	NCT06475989	Map
AR	CARTI Cancer Center	Little Rock72205	NCT06475989	Map
CA	Sutter Auburn	Auburn95602	NCT02693535	Map
CA	Sutter Alta Bates	Berkeley94705	NCT02693535	Map
CA	Providence Saint Joseph Medical Center/Disney Family Cancer Center	Burbank91505	NCT06475989	Map
CA	City of Hope Medical Center	Duarte91010	NCT03975231	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT06475989	Map
CA	Children's Hospital Los Angeles	Los Angeles90027	NCT04485559	Map
CA	Children's Hospital Los Angeles	Los Angeles900027	NCT05849662	Map
CA	LACN Aneheim Flagship Office	Los Angeles92805	NCT05874414	Map
CA	The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate	Los Angeles90025	NCT02693535	Map
CA	USC Norris Comprehensive Cancer Center	Los Angeles90033	NCT05874414	Map
CA	Providence Queen of The Valley	Napa94558	NCT06475989	Map
CA	Kaiser Permanente - Oakland Medical Center	Oakland94611	NCT02693535	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT06475989	Map
CA	Stanford Cancer Institute Palo Alto	Palo Alto94304	NCT06475989	Map
CA	Sutter Palo Alto Medical Foundation: Palo Alto	Palo Alto94301	NCT02693535	Map
CA	Kaiser Permanente - Roseville Medical Center	Roseville95661	NCT02693535	Map
CA	Sutter Roseville	Roseville95661	NCT02693535	Map
CA	Kaiser Permanente - Sacramento Medical Center	Sacramento95814	NCT02693535	Map
CA	Sutter Sacramento	Sacramento95816	NCT02693535	Map
CA	University of California, San Diego Rady Children's Hospital	San Diego92123	NCT04485559	Map
CA	California Pacific Medical Center Research Institute	San Francisco94115	NCT02693535	Map
CA	Kaiser Permanente - San Francisco Medical Center	San Francisco94115	NCT02693535	Map
CA	Kaiser Permanente - South San Francisco Medical Center	San Francisco94080	NCT02693535	Map
CA	Sutter Cancer Research Consortium	San Francisco94115	NCT02693535	Map
CA	University of California San Francisco	San Francisco94158	NCT05849662	Map
CA	University of California, San Francisco	San Francisco94143	NCT04485559	Map
CA	University of California, San Francisco	San Francisco94143	NCT07110246	Map
CA	Kaiser Permanente - San Jose Medical Center	San Jose95119	NCT02693535	Map
CA	Kaiser Permanente - San Leandro Medical Center	San Leandro94577	NCT02693535	Map
CA	Sutter Sansum Clinic	Santa Barbara93105	NCT02693535	Map
CA	Kaiser Permanente - Santa Clara Medical Center	Santa Clara95051	NCT02693535	Map
CA	Sutter Palo Alto Medical Foundation: Fremont	Santa Cruz994538	NCT02693535	Map
CA	Sutter Palo Alto Medical Foundation: Santa Cruz	Santa Cruz95065	NCT02693535	Map
CA	Providence Medical Foundation - Santa Rosa	Santa Rosa95403	NCT06475989	Map
CA	Providence Santa Rosa Memorial Hospital	Santa Rosa95405	NCT06475989	Map
CA	Sutter Palo Alto Medical Foundation: Sunnyvale	Sunnyvale94086	NCT02693535	Map
CA	Kaiser Permanente - Vallejo Medical Center	Vallejo94589	NCT02693535	Map
CA	Kaiser Permanente - Walnut Creek Medical Center	Walnut Creek94596	NCT02693535	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT06475989	Map
CO	Children's Hospital of Colorado	Denver80045	NCT05849662	Map
CO	UCHealth Highlands Ranch Hospital	Highlands Ranch80129	NCT06475989	Map
CT	Saint Vincent's Medical Center (SVMC)	Bridgeport06606	NCT02693535	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center at Glastonbury	Glastonbury06033	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center at Greenwich	Greenwich06830	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT06475989	Map
CT	Hartford Hospital	Hartford06102	NCT02693535	Map
CT	Smilow Cancer Hospital Care Center at Saint Francis	Hartford06105	NCT06475989	Map
CT	Midstate Medical Center (MSMC)	Meriden06451	NCT02693535	Map
CT	The Hospital of Central Connecticut (HOCC) Cancer Center	New Britain06053	NCT02693535	Map
CT	Smilow Cancer Center/Yale-New Haven Hospital	New Haven06510	NCT06475989	Map
CT	Yale University	New Haven06520	NCT06475989	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT06475989	Map
CT	William W. Backus Hospital	Norwich06360	NCT02693535	Map
CT	Smilow Cancer Hospital Care Center at Long Ridge	Stamford06902	NCT06475989	Map
CT	Charlotte Hungerford	Torrington06790	NCT02693535	Map
CT	Smilow Cancer Hospital-Torrington Care Center	Torrington06790	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT06475989	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT06475989	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT06475989	Map
CT	Windham Hospital (WH)	Willimantic06226	NCT02693535	Map
DC	Children's National Medical Center	Washington D.C.20010	NCT04485559	Map
DC	Children's National Medical Center	Washington D.C.20010	NCT05849662	Map
FL	University of Miami/Sylvester Cancer Institute - Aventura	Aventura33180	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Lennar	Coral Gables33146	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Deerfield Beach	Deerfield Beach33442	NCT02693535	Map
FL	Holy Cross Hospital	Fort Lauderdale33308	NCT02693535	Map
FL	Holy Cross Hospital	Fort Lauderdale33308	NCT06475989	Map
FL	University of Florida	Gainesville32610-0265	NCT04485559	Map
FL	University of Florida Health	Gainesville32610	NCT02693535	Map
FL	Mayo Clinic in Florida	Jacksonville32224-9980	NCT06475989	Map
FL	University of Miami	Miami33136	NCT05849662	Map
FL	University of Miami Sylvester Comprehensive Cancer Center	Miami33136	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Alex's Place	Miami33136	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building	Miami33136	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Kendall	Miami33176	NCT02693535	Map
FL	University of Miami/Sylvester Cancer Institute - Sole Mia	Miami33181	NCT02693535	Map
FL	Orlando Health	Orlando32806	NCT05874414	Map
FL	University of Miami/Sylvester Cancer Institute - Plantation	Plantation33324	NCT02693535	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05874414	Map
GA	Cancer Treatment Centers of America - Atlanta	Atlanta30265	NCT02693535	Map
GA	Children's Hospital of Atlanta	Atlanta30322	NCT05849662	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06475989	Map
GA	Emory University Winship Cancer Institute	Atlanta30322	NCT02693535	Map
GA	Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion	Savannah31405	NCT02693535	Map
GA	Lewis Cancer & Research Pavilion	Savannah31405	NCT02693535	Map
GA	Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute	Savannah31405	NCT02693535	Map
GA	Summit Cancer Care	Savannah31405	NCT02693535	Map
HI	The Queen's Medical Center - West Oahu	‘Ewa Beach96706	NCT02693535	Map
HI	The Queen's Medical Center - Kuakini	Honolulu96817	NCT02693535	Map
HI	The Queen's Medical Center - POB I	Honolulu96813	NCT02693535	Map
HI	The Queen's Medical Center - Punchbowl	Honolulu96813	NCT02693535	Map
ID	Saint Alphonsus Cancer Care Center-Boise	Boise83706	NCT06475989	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT06475989	Map
ID	Saint Alphonsus Cancer Care Center-Caldwell	Caldwell83605	NCT06475989	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT06475989	Map
ID	Saint Luke's Cancer Institute - Fruitland	Fruitland83619	NCT06475989	Map
ID	Idaho Urologic Institute-Meridian	Meridian83642	NCT06475989	Map
ID	Saint Luke's Cancer Institute - Meridian	Meridian83642	NCT06475989	Map
ID	Saint Alphonsus Cancer Care Center-Nampa	Nampa83687	NCT06475989	Map
ID	Saint Luke's Cancer Institute - Nampa	Nampa83687	NCT06475989	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT06475989	Map
ID	Kootenai Clinic Cancer Services - Sandpoint	Sandpoint83864	NCT06475989	Map
ID	Saint Luke's Cancer Institute - Twin Falls	Twin Falls83301	NCT06475989	Map
IL	OSF Saint Anthony's Health Center	Alton62002	NCT06475989	Map
IL	Advocate Outpatient Center - Aurora	Aurora60506	NCT06475989	Map
IL	Advocate Good Shepherd Hospital	Barrington60010	NCT06475989	Map
IL	Advocate Illinois Masonic Medical Center	Chicago60657	NCT06475989	Map
IL	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago60611	NCT04485559	Map
IL	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago60611	NCT06712875	Map
IL	Cancer Treatment Centers of America-Chicago	Chicago60099	NCT02693535	Map
IL	Lurie Children's Hospital of Chicago	Chicago60611	NCT05849662	Map
IL	Northwestern University	Chicago60611	NCT06475989	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT06475989	Map
IL	University Of Chicago Medical Center	Chicago60637	NCT05874414	Map
IL	University of Illinois	Chicago60612	NCT06475989	Map
IL	AMG Crystal Lake - Oncology	Crystal Lake60014	NCT06475989	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT06475989	Map
IL	Advocate Good Samaritan Hospital	Downers Grove60515	NCT06475989	Map
IL	Advocate Sherman Hospital	Elgin60123	NCT06475989	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT06475989	Map
IL	Northwestern Medicine Glenview Outpatient Center	Glenview60026	NCT06475989	Map
IL	Northwestern Medicine Grayslake Outpatient Center	Grayslake60030	NCT06475989	Map
IL	Advocate South Suburban Hospital	Hazel Crest60429	NCT06475989	Map
IL	Northwestern Medicine Lake Forest Hospital	Lake Forest60045	NCT06475989	Map
IL	AMG Libertyville - Oncology	Libertyville60048	NCT06475989	Map
IL	Condell Memorial Hospital	Libertyville60048	NCT06475989	Map
IL	SSM Health Good Samaritan	Mount Vernon62864	NCT06475989	Map
IL	UC Comprehensive Cancer Center at Silver Cross	New Lenox60451	NCT06475989	Map
IL	Advocate Christ Medical Center	Oak Lawn60453-2699	NCT06475989	Map
IL	Advocate Outpatient Center - Oak Lawn	Oak Lawn60453	NCT06475989	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT06475989	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT06475989	Map
IL	Advocate High Tech Medical Park	Palos Heights60463	NCT06475989	Map
IL	Advocate Lutheran General Hospital	Park Ridge60068	NCT06475989	Map
IL	Memorial Hospital East	Shiloh62269	NCT06475989	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT06475989	Map
IN	UChicago Medicine Northwest Indiana	Crown Point46307	NCT06475989	Map
IN	Community Health Network (The University of Texas MD Anderson Cancer Center)	Indianapolis46250	NCT02693535	Map
IN	Indiana University/Riley Hospital for Children	Indianapolis46202	NCT05849662	Map
IN	Riley Hospital for Children	Indianapolis46202	NCT04485559	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT06475989	Map
IA	University of Iowa Healthcare Cancer Services Quad Cities	Bettendorf52722	NCT06475989	Map
IA	Saint Anthony Regional Hospital	Carroll51401	NCT06475989	Map
IA	Mercy Hospital	Cedar Rapids52403	NCT06475989	Map
IA	Oncology Associates at Mercy Medical Center	Cedar Rapids52403	NCT06475989	Map
IA	Mercy Cancer Center-West Lakes	Clive50325	NCT06475989	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT06475989	Map
IA	Heartland Oncology and Hematology LLP	Council Bluffs51503	NCT06475989	Map
IA	Methodist Jennie Edmundson Hospital	Council Bluffs51503	NCT06475989	Map
IA	Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ	Council Bluffs51503	NCT06475989	Map
IA	Greater Regional Medical Center	Creston50801	NCT06475989	Map
IA	Broadlawns Medical Center	Des Moines50314	NCT06475989	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT06475989	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT06475989	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT06475989	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT06475989	Map
IA	UI Healthcare Mission Cancer and Blood - Fort Dodge	Fort Dodge50501	NCT06475989	Map
IA	University of Iowa/Holden Comprehensive Cancer Center	Iowa City52242	NCT06475989	Map
IA	UI Healthcare Mission Cancer and Blood - Pella	Pella50219	NCT06475989	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT06475989	Map
IA	Mercy Medical Center-West Lakes	West Des Moines50266	NCT06475989	Map
IA	The Iowa Clinic PC	West Des Moines50266	NCT06475989	Map
KS	Central Care Cancer Center - Garden City	Garden City67846	NCT06475989	Map
KS	Central Care Cancer Center - Great Bend	Great Bend67530	NCT06475989	Map
KS	Mercy Hospital Pittsburg	Pittsburg66762	NCT06475989	Map
KY	Markey Cancer Center	Lexington40536	NCT04903119	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT06475989	Map
KY	University of Louisville-James Graham Brown Cancer Center	Louisville40202	NCT03899155	Map
ME	Harold Alfond Center for Cancer Care	Augusta04330	NCT02693535	Map
ME	Jackson Laboratory - Maine Cancer Genomics Initiative	Augusta04330	NCT02693535	Map
ME	Waldo County General Hospital	Belfast04915	NCT02693535	Map
ME	SMHC Cancer Care and Blood Disorders -Biddeford	Biddeford04005	NCT02693535	Map
ME	Northern Light Cancer Care	Brewer04412	NCT02693535	Map
ME	Raish Peavey Haskell Children's Cancer and Treatment Center	Brewer04412	NCT02693535	Map
ME	MaineHealth Cancer Care -Brunswick	Brunswick04011	NCT02693535	Map
ME	New England Cancer Specialist	Kennebunk04043	NCT02693535	Map
ME	York Hopsital Oncology & Infusion Care in Kittery	Kittery03904	NCT02693535	Map
ME	Stephens Memorial Hospital	Norway04268	NCT02693535	Map
ME	Penobscot Bay Medical Center	Rockport04856	NCT02693535	Map
ME	SMHC Cancer Care and Blood Disorders -Sandford	Sanford04073	NCT02693535	Map
ME	Maine Children's Cancer Program	Scarborough04074	NCT02693535	Map
ME	Maine Medical Partner's Women's Health	Scarborough04074	NCT02693535	Map
ME	New England Cancer Specialist	Scarborough04074	NCT02693535	Map
ME	MaineHealth Cancer Care -South Portland	South Portland04106	NCT02693535	Map
ME	New England Cancer Specialist	Topsham04086	NCT02693535	Map
ME	York Hospital Oncology & Infusion Care in Wells	Wells04090	NCT02693535	Map
ME	York Hospital Oncology & Infusion Care in York	York Village03909	NCT02693535	Map
MD	John Hopkins Medical Center	Baltimore21287	NCT07110246	Map
MD	John Hopkins University	Baltimore21287	NCT04485559	Map
MD	Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center	Baltimore21287	NCT05372354	Map
MD	Sidney Kimmel Cancer Center at Johns Hopkins	Baltimore21231	NCT05849662	Map
MD	University of Maryland/Greenebaum Cancer Center	Baltimore21201	NCT06475989	Map
MA	Dana_Farber Cancer Institute (DFCI)	Boston02215	NCT03899155	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05372354	Map
MI	MyMichigan Medical Center Gratiot	Alma48801	NCT06475989	Map
MI	MyMichigan Medical Center Alpena	Alpena49707	NCT06475989	Map
MI	C.S. Mott Children's Hospital	Ann Arbor48109	NCT05849662	Map
MI	Trinity Health Ann Arbor Hospital	Ann Arbor48106	NCT02693535	Map
MI	Trinity Health IHA - Obstetrics and Gynecology West Arbor	Ann Arbor48103	NCT06475989	Map
MI	Trinity Health Saint Joseph Mercy Hospital Ann Arbor	Ann Arbor48106	NCT06475989	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT06475989	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT06475989	Map
MI	Trinity Health Medical Center - Brighton	Brighton48114	NCT06475989	Map
MI	University of Michigan - Brighton Center for Specialty Care	Brighton48116	NCT06475989	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT06475989	Map
MI	Trinity Health Medical Center - Canton	Canton48188	NCT06475989	Map
MI	Chelsea Hospital	Chelsea48118	NCT06475989	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT06475989	Map
MI	Hematology Oncology Consultants-Clarkston	Clarkston48346	NCT06475989	Map
MI	Newland Medical Associates-Clarkston	Clarkston48346	NCT06475989	Map
MI	Henry Ford Health Saint John Hospital	Detroit48236	NCT02693535	Map
MI	Henry Ford Health Saint John Hospital	Detroit48236	NCT06475989	Map
MI	Henry Ford River District Hospital	East China Township48054	NCT06475989	—
MI	Cancer Hematology Centers - Flint	Flint48503	NCT06475989	Map
MI	Genesee Hematology Oncology PC	Flint48503	NCT06475989	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT02693535	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT06475989	Map
MI	Hurley Medical Center	Flint48503	NCT06475989	Map
MI	MyMichigan Medical Center Gladwin	Gladwin48624	NCT06475989	Map
MI	Cancer Research Consortium of West Michigan	Grand Rapids49503	NCT02693535	Map
MI	START Mid West	Grand Rapids49546	NCT06804824	Map
MI	Henry Ford Saint John Hospital - Academic	Grosse Pointe Woods48236	NCT06475989	Map
MI	Henry Ford Saint John Hospital - Breast	Grosse Pointe Woods48236	NCT06475989	Map
MI	Henry Ford Saint John Hospital - Van Elslander	Grosse Pointe Woods48236	NCT06475989	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT02693535	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT06475989	Map
MI	Trinity Health Livonia Hospital	Livonia48154	NCT02693535	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT06475989	Map
MI	Henry Ford Saint John Hospital - Macomb Medical	Macomb48044	NCT06475989	Map
MI	Henry Ford Warren Hospital - Breast Macomb	Macomb48044	NCT06475989	Map
MI	MyMichigan Medical Center Midland	Midland48670	NCT06475989	Map
MI	MyMichigan Medical Center Mount Pleasant	Mount Pleasant48858	NCT06475989	Map
MI	Hope Cancer Center	Pontiac48341	NCT06475989	Map
MI	Michigan Healthcare Professionals Pontiac	Pontiac48341	NCT06475989	Map
MI	Newland Medical Associates-Pontiac	Pontiac48341	NCT06475989	Map
MI	Trinity Health Oakland Hospital	Pontiac48341	NCT02693535	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT06475989	Map
MI	MyMichigan Medical Center Saginaw	Saginaw48601	NCT02693535	Map
MI	MyMichigan Medical Center Saginaw	Saginaw48601	NCT06475989	Map
MI	MyMichigan Medical Center Tawas	Tawas City48764	NCT06475989	Map
MI	Michigan Cancer Research Consortium	Traverse City48341	NCT02693535	Map
MI	Henry Ford Health Warren Hospital	Warren48093	NCT02693535	Map
MI	Henry Ford Health Warren Hospital	Warren48093	NCT06475989	Map
MI	Henry Ford Madison Heights Hospital - Breast	Warren48093	NCT06475989	Map
MI	Henry Ford Warren Hospital - GLCMS	Warren48093	NCT06475989	Map
MI	Huron Gastroenterology PC	Ypsilanti48106	NCT06475989	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT06475989	Map
MN	Sanford Joe Lueken Cancer Center	Bemidji56601	NCT06475989	Map
MN	Minnesota Oncology - Burnsville	Burnsville55337	NCT06475989	Map
MN	Cambridge Medical Center	Cambridge55008	NCT06475989	Map
MN	Minnesota Oncology Hematology PA-Chaska	Chaska55318	NCT06475989	Map
MN	Mercy Hospital	Coon Rapids55433	NCT06475989	Map
MN	Minnesota Oncology - Coon Rapids	Coon Rapids55433	NCT06475989	Map
MN	Fairview Southdale Hospital	Edina55435	NCT06475989	Map
MN	Minnesota Oncology - Edina	Edina55435	NCT06475989	Map
MN	Fairview Clinics and Surgery Center Maple Grove	Maple Grove55369	NCT06475989	Map
MN	Minnesota Oncology - Maple Grove	Maple Grove55369	NCT06475989	Map
MN	Minnesota Oncology Hematology PA-Maplewood	Maplewood55109	NCT06475989	Map
MN	Saint John's Hospital - Healtheast	Maplewood55109	NCT06475989	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT06475989	Map
MN	Children's Minnesota	Minneapolis55404	NCT04485559	Map
MN	Health Partners Inc	Minneapolis55454	NCT06475989	Map
MN	Hennepin County Medical Center	Minneapolis55415	NCT06475989	Map
MN	Monticello Cancer Center	Monticello55362	NCT06475989	Map
MN	New Ulm Medical Center	New Ulm56073	NCT06475989	Map
MN	Fairview Northland Medical Center	Princeton55371	NCT06475989	Map
MN	North Memorial Medical Health Center	Robbinsdale55422	NCT06475989	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06475989	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT06475989	Map
MN	Regions Hospital	Saint Paul55101	NCT06475989	Map
MN	United Hospital	Saint Paul55102	NCT06475989	Map
MN	Saint Francis Regional Medical Center	Shakopee55379	NCT06475989	Map
MN	Lakeview Hospital	Stillwater55082	NCT06475989	Map
MN	Sanford Thief River Falls Medical Center	Thief River Falls56701	NCT06475989	Map
MN	Ridgeview Medical Center	Waconia55387	NCT06475989	Map
MN	Rice Memorial Hospital	Willmar56201	NCT06475989	Map
MN	Minnesota Oncology Hematology PA-Woodbury	Woodbury55125	NCT06475989	Map
MN	Sanford Cancer Center Worthington	Worthington56187	NCT06475989	Map
MN	Fairview Lakes Medical Center	Wyoming55092	NCT06475989	Map
MO	Mercy Oncology and Hematology - Clayton-Clarkson	Ballwin63011	NCT06475989	Map
MO	Central Care Cancer Center - Bolivar	Bolivar65613	NCT06475989	Map
MO	Cox Cancer Center Branson	Branson65616	NCT06475989	Map
MO	Mercy Cancer Center - Cape Girardeau	Cape Girardeau63703	NCT06475989	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT06475989	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT06475989	Map
MO	Freeman Health System	Joplin64804	NCT06475989	Map
MO	Mercy Hospital Joplin	Joplin64804	NCT06475989	Map
MO	Children's Mercy Hospital	Kansas City64108	NCT05849662	Map
MO	Lake Regional Hospital	Osage Beach65065	NCT06475989	Map
MO	Mercy Clinic-Rolla-Cancer and Hematology	Rolla65401	NCT06475989	Map
MO	Phelps Health Delbert Day Cancer Institute	Rolla65401	NCT06475989	Map
MO	Heartland Regional Medical Center	Saint Joseph64506	NCT06475989	Map
MO	CoxHealth South Hospital	Springfield65807	NCT06475989	Map
MO	Mercy Hospital Springfield	Springfield65804	NCT06475989	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT06475989	Map
MO	Mercy Hospital South	St Louis63128	NCT06475989	Map
MO	Mercy Infusion Center - Chippewa	St Louis63109	NCT06475989	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT06475989	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT06475989	Map
MO	St. Louis Children's Hospital Washington University in St. Louis	St Louis63110	NCT07110246	Map
MO	Washington University in St. Louis	St Louis63110	NCT04485559	Map
MO	Washington University School of Medicine	St Louis63110	NCT06475989	Map
MO	Mercy Hospital Washington	Washington63090	NCT06475989	Map
MT	Community Hospital of Anaconda	Anaconda59711	NCT06475989	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT06475989	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT06475989	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT06475989	Map
MT	Great Falls Clinic	Great Falls59405	NCT06475989	Map
MT	Hi-Line Sletten Cancer Center	Havre59501	NCT06475989	Map
MT	Benefis Helena Specialty Center	Helena59601	NCT06475989	Map
MT	Logan Health Medical Center	Kalispell59901	NCT06475989	Map
MT	Community Medical Center	Missoula59804	NCT06475989	Map
MT	Saint Patrick Hospital - Community Hospital	Missoula59802	NCT06475989	Map
NE	Nebraska Cancer Specialists/Oncology Hematology West PC - MECC	Omaha68114	NCT06475989	Map
NE	Nebraska Methodist Hospital	Omaha68114	NCT06475989	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT02693535	Map
NH	NH Oncology - Hematology, PA	Concord03103	NCT02693535	Map
NH	Solinsky Center for Cancer Care	Manchester03103	NCT02693535	Map
NH	New England Cancer Specialist	Portsmouth03801	NCT02693535	Map
NJ	Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT07477457	Map
NJ	John Theurer Cancer Center at Hackensack UMC	Hackensack07601	NCT05372354	Map
NJ	Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center	Hackensack07601	NCT04485559	Map
NJ	Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)	Middletown07748	NCT07477457	Map
NJ	Memorial Sloan Kettering at Bergen (Limited Protocol Activities)	Montvale07645	NCT07477457	Map
NM	Lovelace Medical Center - Saint Joseph Square	Albuquerque87102	NCT02693535	Map
NM	Presbyterian Kaseman Hospital	Albuquerque87110	NCT02693535	Map
NM	The University of New Mexico Comprehensive Cancer Center	Albuquerque87131	NCT02693535	Map
NM	Memorial Medical Center	Las Cruces88011	NCT02693535	Map
NM	Presbyterian Rust Medical Center	Rio Rancho87124	NCT02693535	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT03899155	Map
NY	Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities)	Commack11725	NCT07477457	Map
NY	Memorial Sloan Kettering at Westchester (Limited Protocol Activities)	Harrison10604	NCT07477457	Map
NY	Northwell Health Monter Cancer Center	Lake Success11042	NCT02693535	Map
NY	NYU Langone Hematology Oncology Associates-Mineola	Mineola11501	NCT03899155	Map
NY	Northern Westchester Hospital	Mount Kisco10549	NCT02693535	Map
NY	Cohen Children's Medical Center	New Hyde Park11040	NCT02693535	Map
NY	Manhattan Eye, Ear, and Throat Hospital	New York10065	NCT02693535	Map
NY	Memorial Sloan Kettering Cancer Center	New York10021	NCT05372354	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05849662	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activites)	New York10065	NCT07477457	Map
NY	New York University	New York10016	NCT04485559	Map
NY	Staten Island University Hospital	New York10305	NCT02693535	Map
NY	Queens Cancer Center	Rego Park11374	NCT02693535	Map
NY	Phelps Hospital	Sleepy Hollow10591	NCT02693535	Map
NY	Memorial Sloan Kettering at Nassau (Limited Protocol Activities)	Uniondale11553	NCT07477457	Map
NC	Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT02693535	Map
NC	UNC Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT06475989	Map
NC	Atrium Health's Levine Cancer Institute	Charlotte28277	NCT02693535	Map
NC	Duke University Medical Center	Durham27710	NCT06475989	Map
NC	Duke University Medical Center	Durham27710	NCT07110246	Map
ND	Sanford Bismarck Medical Center	Bismarck58501	NCT06475989	Map
ND	Sanford Health- Bismarck	Bismarck58501	NCT02693535	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT06475989	Map
ND	Sanford Health- Fargo	Fargo58122	NCT02693535	Map
ND	Sanford Medical Center Fargo	Fargo58104	NCT06475989	Map
ND	Sanford Roger Maris Cancer Center	Fargo58122	NCT06475989	Map
ND	Sanford South University Medical Center	Fargo58103	NCT06475989	Map
ND	Southpointe-Sanford Medical Center Fargo	Fargo58103	NCT06475989	Map
OH	Cincinnati Children's Hospital Medical Center	Cincinnati45229	NCT05849662	Map
OH	Oncology Hematology Care	Cincinnati45242	NCT03899155	Map
OH	University of Cincinnati Medical Center	Cincinnati45219	NCT02693535	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT03975231	Map
OH	The Ohio University	Columbus43210	NCT03899155	Map
OH	Kettering Health	Kettering45429	NCT02693535	Map
OH	West Chester Hospital	West Chester45069	NCT02693535	Map
OK	Cancer Centers of Southwest Oklahoma Research	Lawton73505	NCT06475989	Map
OK	Mercy Hospital Oklahoma City	Oklahoma City73120	NCT06475989	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06475989	Map
OR	Saint Alphonsus Cancer Care Center-Baker City	Baker City97814	NCT06475989	Map
OR	Saint Charles Health System	Bend97701	NCT06475989	Map
OR	Clackamas Radiation Oncology Center	Clackamas97015	NCT06475989	Map
OR	Bay Area Hospital	Coos Bay97420	NCT06475989	Map
OR	Providence Hood River Memorial Hospital	Hood River97031	NCT06475989	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT06475989	Map
OR	Saint Alphonsus Cancer Care Center-Ontario	Ontario97914	NCT06475989	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT06475989	Map
OR	Oregon Health & Science University	Portland97239	NCT05849662	Map
OR	Oregon Health and Science University	Portland97239	NCT06475989	Map
OR	Providence Health & Services	Portland97213	NCT02693535	Map
OR	Providence Portland Medical Center	Portland97213	NCT06475989	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT06475989	Map
OR	Saint Charles Health System-Redmond	Redmond97756	NCT06475989	Map
PA	Lehigh Valley Hospital - Cedar Crest	Allentown18103	NCT02693535	Map
PA	Lehigh Valley Hospital-Cedar Crest	Allentown18103	NCT06475989	Map
PA	Lehigh Valley Hospital - Muhlenberg	Bethlehem18017	NCT06475989	Map
PA	Lehigh Valley Hospital- Muhlenberg	Bethlehem18017	NCT02693535	Map
PA	Pocono Medical Center	East Stroudsburg18301	NCT02693535	Map
PA	Pocono Medical Center	East Stroudsburg18301	NCT06475989	Map
PA	St. Luke's University Health Network	Easton18045	NCT04903119	Map
PA	UPMC Hillman Cancer Center Erie	Erie16505	NCT06475989	Map
PA	Lehigh Valley Hospital-Hazleton	Hazleton18201	NCT02693535	Map
PA	Lehigh Valley Hospital-Hazleton	Hazleton18201	NCT06475989	Map
PA	Lancaster General Health	Lancaster17601	NCT03899155	Map
PA	Children's Hospital of Philadelphia	Philadelphia19104	NCT04485559	Map
PA	Children's Hospital of Philadelphia	Philadelphia19104	NCT05849662	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT02693535	Map
PA	University of Pennsylvania/Abramson Cancer Center	Philadelphia19104	NCT06475989	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT06475989	Map
RI	Smilow Cancer Hospital Care Center - Westerly	Westerly02891	NCT06475989	Map
SC	SC Cancer Specialists at St. Joseph's/Candler Bluffton	Bluffton29910	NCT02693535	Map
SC	St. Joseph's/Candler Smith	Bluffton29910	NCT02693535	Map
SC	Summit Cancer Care at St. Josph's/Candler Bluffton	Bluffton29910	NCT02693535	Map
SC	Medical University of South Carolina	Charleston29425	NCT06475989	Map
SC	South Carolina Cancer Specialists	Hilton Head Island29926	NCT02693535	Map
SD	Sanford Cancer Center Oncology Clinic	Sioux Falls57104	NCT06475989	Map
SD	Sanford Cancer Center Oncology Clinic and Pharmacy	Sioux Falls57104	NCT02693535	Map
SD	Sanford USD Medical Center - Sioux Falls	Sioux Falls57117-5134	NCT06475989	Map
TN	St. Jude Children's Research Hospital	Memphis38105	NCT07110246	Map
TN	St. Jude Children's Research Hospital Memphis	Memphis38105	NCT05849662	Map
TN	Tennesse Oncology	Nashville37203	NCT03899155	Map
TN	Tennessee Oncology - Nashville / Sarah Cannon Research Institute	Nashville37203	NCT02693535	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT06475989	Map
TN	Vanderbilt-Ingram Cancer Center	Nashville37232	NCT04903119	Map
TX	NEXT Austin	Austin78758	NCT06804824	Map
TX	University Of Texas Southwestern Medical Center	Dallas75235	NCT04485559	Map
TX	Cook Children's Health Care System	Fort Worth76104	NCT06582745	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT02693535	Map
TX	Univ of Texas-M.D. Anderson Cancer Center	Houston77030	NCT03975231	Map
TX	University of Texas, MD Anderson Cancer Center	Houston77030	NCT05874414	Map
TX	NEXT Dallas	Irving75039	NCT06804824	Map
TX	NEXT San Antonio	San Antonio78299	NCT06804824	Map
TX	START San Antonio	San Antonio78229	NCT06804824	Map
UT	Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center	Cedar City84720	NCT02693535	Map
UT	START Mountain	Ogden84401	NCT06804824	Map
UT	Huntsman Cancer Institute/University of Utah	Salt Lake City84112	NCT06475989	Map
UT	Intermountain Healthcare	Salt Lake City84107	NCT02693535	Map
UT	Primary Children's Hospital	Salt Lake City84113	NCT05849662	Map
UT	University of Utah	Salt Lake City84112	NCT07110246	Map
UT	Dixie Regional Medical Center-River Road Campus	St. George84770	NCT02693535	Map
VA	University of Virginia Comprehensive Cancer Center	Charlottesville22908	NCT05874414	Map
VA	Inova Schar Cancer Institute	Fairfax22042	NCT02693535	Map
VA	NEXT Virginia	Fairfax22031	NCT06804824	Map
WA	Providence Regional Cancer System-Aberdeen	Aberdeen98520	NCT06475989	Map
WA	PeaceHealth Saint Joseph Medical Center	Bellingham98225	NCT06475989	Map
WA	Northwest Medical Specialties	Bonney Lake98391	NCT02693535	Map
WA	Providence Regional Cancer System-Centralia	Centralia98531	NCT06475989	Map
WA	Swedish Cancer Institute-Edmonds	Edmonds98026	NCT06475989	Map
WA	Providence Regional Cancer Partnership	Everett98201	NCT06475989	Map
WA	Northwest Medical Specialties	Federal Way98003	NCT02693535	Map
WA	Northwest Medical Specialties	Gig Harbor98332	NCT02693535	Map
WA	Swedish Cancer Institute-Issaquah	Issaquah98029	NCT06475989	Map
WA	Kadlec Clinic Hematology and Oncology	Kennewick99336	NCT06475989	Map
WA	Providence Regional Cancer System-Lacey	Lacey98503	NCT06475989	Map
WA	PeaceHealth Saint John Medical Center	Longview98632	NCT06475989	Map
WA	Skagit Regional Health Cancer Care Center	Mount Vernon98274	NCT06475989	Map
WA	Northwest Medical Specialties	Olympia98502	NCT02693535	Map
WA	Northwest Medical Specialties	Puyallup98373	NCT02693535	Map
WA	Seattle Children's Hospital	Seattle98105	NCT05849662	Map
WA	Swedish Cancer Institute	Seattle98104	NCT02693535	Map
WA	Swedish Medical Center-Ballard Campus	Seattle98107	NCT06475989	Map
WA	Swedish Medical Center-Cherry Hill	Seattle98122-5711	NCT06475989	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT06475989	Map
WA	PeaceHealth United General Medical Center	Sedro-Woolley98284	NCT06475989	Map
WA	Cancer Care Northwest - Spokane South	Spokane99202	NCT06475989	Map
WA	Cancer Care Northwest-North Spokane	Spokane99218	NCT06475989	Map
WA	Cancer Care Northwest-Valley	Spokane99216	NCT06475989	Map
WA	Northwest Medical Specialties	Tacoma98405	NCT02693535	Map
WA	PeaceHealth Southwest Medical Center	Vancouver98664	NCT06475989	Map
WA	Providence Saint Mary Regional Cancer Center	Walla Walla99362	NCT06475989	Map
WI	Aurora Cancer Care - Burlington	Burlington53105	NCT02693535	Map
WI	Aurora Cancer Care-Southern Lakes VLCC	Burlington53105	NCT06475989	Map
WI	Aurora Saint Luke's South Shore	Cudahy53110	NCT06475989	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT06475989	Map
WI	Aurora Health Care - Germantown Health Center	Germantown53022	NCT02693535	Map
WI	Aurora Health Care Germantown Health Center	Germantown53022	NCT06475989	Map
WI	Aurora Cancer Care - Grafton	Grafton53024	NCT02693535	Map
WI	Aurora Cancer Care-Grafton	Grafton53024	NCT06475989	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT02693535	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT06475989	Map
WI	Aurora Cancer Care - Kenosha South	Kenosha53142	NCT02693535	Map
WI	Aurora Cancer Care-Kenosha South	Kenosha53142	NCT06475989	Map
WI	Aurora Bay Area Medical Center	Marinette54143	NCT02693535	Map
WI	Aurora Bay Area Medical Group-Marinette	Marinette54143	NCT06475989	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT06475989	Map
WI	Aurora Cancer Care Milwaukee	Milwaukee53209	NCT02693535	Map
WI	Aurora Cancer Care-Milwaukee	Milwaukee53209	NCT06475989	Map
WI	Aurora Saint Luke's Medical Center	Milwaukee53215	NCT06475989	Map
WI	Aurora Sinai Medical Center	Milwaukee53223	NCT02693535	Map
WI	Aurora Sinai Medical Center	Milwaukee53233	NCT06475989	Map
WI	Aurora St. Luke's Medical Center	Milwaukee53215	NCT02693535	Map
WI	Aurora West Allis Medical Center	Milwaukee53227	NCT02693535	Map
WI	Froedtert Hospital and the Medical College of Wisconsin	Milwaukee53226	NCT05874414	Map
WI	Marshfield Medical Center - Minocqua	Minocqua54548	NCT06475989	Map
WI	Cancer Center of Western Wisconsin	New Richmond54017	NCT06475989	Map
WI	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh54904	NCT02693535	Map
WI	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh54904	NCT06475989	Map
WI	Aurora Cancer Care - Racine	Racine53406	NCT02693535	Map
WI	Aurora Cancer Care-Racine	Racine53406	NCT06475989	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT06475989	Map
WI	Vince Lombardi Cancer Center	Sheboygan53081	NCT02693535	Map
WI	Vince Lombardi Cancer Clinic-Sheboygan	Sheboygan53081	NCT06475989	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT06475989	Map
WI	Aurora Medical Center in Summit	Summit53066	NCT02693535	—
WI	Aurora Medical Center in Summit	Summit53066	NCT06475989	—
WI	Vince Lombardi Cancer Clinic - Two Rivers	Two Rivers54241	NCT02693535	Map
WI	Vince Lombardi Cancer Clinic-Two Rivers	Two Rivers54241	NCT06475989	Map
WI	Aurora Cancer Care - Milwaukee West	Wauwatosa53226	NCT02693535	Map
WI	Aurora Cancer Care-Milwaukee West	Wauwatosa53226	NCT06475989	Map
WI	Aurora West Allis Medical Center	West Allis53227	NCT06475989	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT06475989	Map
WY	Memorial Hospital of Laramie County	Cheyenne82001	NCT06475989	Map
WY	Billings Clinic-Cody	Cody82414	NCT06475989	Map

Trametinib clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	not yet recruiting	unknown	no longer available	Total
Early P1		1							1
P1	6	8	26	15	7		2		64
P1/P2	6	7	12	4	2	2	1		34
P2	22	25	29	13	9	1	9		108
P2/P3			1			2			3
P3	1	3	5	1					10
P4	2	1				1			4
N/A	3	1	8	1		1	1	4	19

Recruiting Trametinib clinical trials (47)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06582745	LCHTargeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib	P2	Langerhans Cell Histiocytosis	75	Jun 2024
NCT04803318	Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors	P2	Solid Tumor, Adult	100	Jan 2021
NCT06119789	MATRIX-RarePrecision Cancer Therapy in Rare Cancers	P2	Rare Malignant Neoplasm	96	Mar 2025
NCT03340506	Dabrafenib and/or Trametinib Rollover Study	P4	Melanoma	100	Dec 2017
NCT07092670	MELAFERTMELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.	—	Melanoma	270	Aug 2025
NCT07110246	PNOC037Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas	P2	BRAF V600 Mutation	96	Nov 2025
NCT05180825	PLGG - MEKTRICPediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy	P2	Grade 1 Glioma	134	May 2022
NCT06475989	Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer	P3	Refractory Differentiated Thyroid Gland Carcinoma	264	Aug 2024
NCT07022834	Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children	P2	Langerhans Cell Histiocytosis (LCH)	20	Jun 2025
NCT04903119	Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma	P1	Metastatic Melanoma	30	Jun 2022
NCT05849662	A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia	P1/P2	Leukemia, Juvenile Myelomonocytic	58	Oct 2024
NCT06653517	NETCAMClinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma	P2	Ameloblastoma	12	Jan 2023
NCT06563999	NUMERNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.	P2	Lung Cancer Stage III	120	Nov 2024
NCT07440290	DETERMINEDETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	P2/P3	Haematological Malignancy	30	Feb 2026
NCT07468071	KontRASt-RRollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments	P1/P2	Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer	40	Jun 2026
NCT03899155	Pan Tumor Rollover Study	P2	Cancer	1,500	Aug 2019
NCT07419932	NeoLATCResponse to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer	—	Thyroid Cancer	120	Dec 2025
NCT06712875	MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas	P1/P2	Low Grade Glioma	27	Apr 2025
NCT05658640	HEM-iSMART DHEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	P1/P2	Acute Lymphoblastic Leukemia, in Relapse	26	Nov 2023
NCT07010393	Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study	P4	Thyroid Neoplasms	335	Jul 2025
NCT06819605	NETCAM-RCTNeoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma	P2/P3	Ameloblastoma	46	Mar 2025
NCT06456138	Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC	P1/P2	KRAS Mutation-Related Tumors	60	Jul 2024
NCT06195228	A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer	P4	Advanced Thyroid Cancer Patients Who Received Target Therapy	800	Jan 2020
NCT02693535	TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	P2	Lymphoma, Non-Hodgkin	4,200	Mar 2016
NCT05275374	ENHANCEXP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	P1/P2	Cancer	221	Dec 2025
NCT03563729	MEMBRAINSMelanoma Metastasized to the Brain and Steroids	P2	Malignant Melanoma	80	Jun 2018
NCT05525273	SwecranioTreatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma	P2	Craniopharyngioma	25	Sep 2023
NCT06962254	Imatinib and Trametinib for KRAS-mutated Solid Tumor	P1	Solid Tumor Cancer	10	May 2025
NCT07477457	A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma	P2	Osteosarcoma	45	Mar 2026
NCT06079333	NEO-ATACTNEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)	P2	Anaplastic Thyroid Cancer	20	Jan 2023
NCT04485559	PNOC021Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)	P1	Recurrent World Health Organization (WHO) Grade II Glioma	50	Dec 2020
NCT02925234	DRUPThe Drug Rediscovery Protocol (DRUP Trial)	P2	Cancer	1,550	Aug 2016
NCT04116541	MegaMOSTA Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.	P2	Malignant Solid Tumor	455	Jan 2020
NCT03975231	Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	P1	BRAF NP_004324.2:p.V600E	6	Sep 2020
NCT06804824	FIHA First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors	P1	Advanced Solid Tumors	220	Feb 2025
NCT04943224	TRAMOptimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients	P2	Histiocytosis	12	Apr 2021
NCT06739395	Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion	P2	Solid Tumor	300	Nov 2024
NCT05988697	Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib	—	NSCLC	36	Nov 2023
NCT06054191	Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations	P2	NSCLC	40	Feb 2024
NCT06555237	MEKinRASMEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies	P2	Cardiomegaly	40	Aug 2024
NCT05159245	FINPROVEThe Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs	P2	Advanced Cancer	250	Dec 2021
NCT05874414	Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma	P1/P2	Cholangiocarcinoma	74	Aug 2023
NCT05372354	BMS-986348A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma	P1/P2	Multiple Myeloma	260	Oct 2022
NCT06532149	EROSERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer	—	NSCLC Stage IV	80	Aug 2024
NCT06362694	Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy	P2	Anaplastic Thyroid Cancer	10	Mar 2024
NCT03631953	ALTREMCombination of Alpelisib and Trametinib in Progressive Refractory Meningiomas	P1	Meningioma	25	Sep 2019
NCT06482086	Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer	P2	Locally Advanced Thyroid Gland Carcinoma	75	Jun 2021

Trametinib clinical trials by indication

Melanoma (38)

NCT	Acronym	Phase	Status	Title
NCT03340506	—	P4	recruiting	Dabrafenib and/or Trametinib Rollover Study
NCT07092670	MELAFERT	N/A	recruiting	MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
NCT04666272	—	N/A	active not recruiting	Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
NCT04417621	—	P2	active not recruiting	Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT01972347	Neo Combi	P2	active not recruiting	Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
NCT02645149	Match Mel	P2	completed	Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma
NCT03026517	—	P1	completed	Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
NCT03501368	—	P1	completed	Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
+ 30 more, see All trials below.

Cancer (18)

NCT	Acronym	Phase	Status	Title
NCT03899155	—	P2	recruiting	Pan Tumor Rollover Study
NCT05275374	ENHANCE	P1/P2	not yet recruiting	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
NCT02925234	DRUP	P2	recruiting	The Drug Rediscovery Protocol (DRUP Trial)
NCT05876806	—	P2	unknown	Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
NCT04801966	TAILOR	N/A	terminated	Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
NCT03543306	—	P2	unknown	Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation
NCT02034110	—	P2	completed	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
NCT02083354	—	P2	completed	Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
+ 10 more, see All trials below.

Metastatic Melanoma (6)

NCT	Acronym	Phase	Status	Title
NCT04903119	—	P1	recruiting	Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
NCT03149029	—	P2	active not recruiting	Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
NCT05611229	—	N/A	completed	Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
NCT02392871	CombiRT	P1/P2	completed	Radiotherapy & Combi in Metastatic Melanoma
NCT02625337	IMPemBra	P2	unknown	Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients
NCT02357732	—	P1	withdrawn	Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

Colorectal Cancer (6)

NCT	Acronym	Phase	Status	Title
NCT03377361	CheckMate 9N9	P1/P2	completed	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
NCT04303403	—	P1	unknown	Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
NCT03714958	TRAHD	P1	completed	Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type
NCT02399943	—	P2	completed	A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
NCT02230553	M14LTK	P1/P2	completed	Lapatinib Plus Trametinib in KRAS Mutant NSCLC
NCT02538627	—	P1	terminated	Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Malignant Melanoma (5)

NCT	Acronym	Phase	Status	Title
NCT03563729	MEMBRAINS	P2	recruiting	Melanoma Metastasized to the Brain and Steroids
NCT04547946	—	N/A	completed	Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
NCT03551626	COMBI-APlus	P3	completed	Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
NCT02410863	BOTTOM	P2	terminated	Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
NCT02296996	—	P2	completed	Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Advanced Lymphoma (5)

NCT	Acronym	Phase	Status	Title
NCT04439279	—	P2	active not recruiting	Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
NCT04439357	—	P2	active not recruiting	Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
NCT04439318	—	P2	active not recruiting	Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
NCT04439292	—	P2	active not recruiting	Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
NCT02465060	—	P2	active not recruiting	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Thyroid Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT07419932	NeoLATC	N/A	recruiting	Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
NCT04544111	—	P2	active not recruiting	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
NCT05182931	I-FIRST	P2	unknown	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
NCT04554680	—	P2	unknown	Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

Anaplastic Thyroid Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT06079333	NEO-ATACT	P2	recruiting	NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
NCT03085056	—	Early P1	active not recruiting	Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
NCT06362694	—	P2	recruiting	Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
NCT04238624	—	P2	active not recruiting	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Ameloblastoma (3)

NCT	Acronym	Phase	Status	Title
NCT06653517	NETCAM	P2	recruiting	Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
NCT06819605	NETCAM-RCT	P2/P3	not yet recruiting	Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
NCT02367859	—	P2	completed	Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Multiple Myeloma (3)

NCT	Acronym	Phase	Status	Title
NCT05372354	BMS-986348	P1/P2	recruiting	A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT03091257	—	P1	active not recruiting	A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT02140840	—	P2	withdrawn	UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

Non-small Cell Lung Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT03087448	NSCLC	P1	terminated	Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT03232892	NF1	P2	terminated	Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
NCT02580708	—	P1/P2	terminated	Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Solid Tumours (3)

NCT	Acronym	Phase	Status	Title
NCT03266159	PK	P2	withdrawn	A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors
NCT01928940	—	P2	completed	Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
NCT01767454	—	P1	completed	Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Advanced Malignant Solid Neoplasm (3)

NCT	Acronym	Phase	Status	Title
NCT03065387	—	P1	active not recruiting	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
NCT02070549	—	P1	completed	Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
NCT01827384	—	P2	completed	MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Advanced Solid Tumors (2)

NCT	Acronym	Phase	Status	Title
NCT04185883	—	P1	active not recruiting	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT06804824	FIH	P1	recruiting	A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

KRAS Mutation-Related Tumors (2)

NCT	Acronym	Phase	Status	Title
NCT06456138	—	P1/P2	not yet recruiting	Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
NCT05071183	—	P1/P2	terminated	A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

NSCLC (2)

NCT	Acronym	Phase	Status	Title
NCT05988697	—	N/A	not yet recruiting	Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib
NCT06054191	—	P2	not yet recruiting	Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Pancreatic Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT05518110	PaTcH	P2	terminated	PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
NCT02428270	—	P2	completed	A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

Solid Tumors (2)

NCT	Acronym	Phase	Status	Title
NCT05668585	—	P1	completed	A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
NCT02705963	—	P1	completed	A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT03225664	—	P1/P2	active not recruiting	Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
NCT05435846	—	P1	terminated	Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Advanced Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT05159245	FINPROVE	P2	recruiting	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
NCT01287546	—	P1	completed	A Study of LY2875358 in Participants With Advanced Cancer

Clinical Stage IV Cutaneous Melanoma AJCC v8 (2)

NCT	Acronym	Phase	Status	Title
NCT04557956	—	P1/P2	active not recruiting	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
NCT04527549	—	P2	terminated	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Non Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT04967079	—	P1	completed	Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
NCT03704688	—	P1/P2	completed	Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Thyroid Gland Anaplastic Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT04675710	—	P2	active not recruiting	Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
NCT04739566	ANAPLAST-NEO	P2	withdrawn	Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer

Non-Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT04892017	DCC-3116	P1	terminated	Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
NCT02974725	—	P1	terminated	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Anaplastic Astrocytoma (2)

NCT	Acronym	Phase	Status	Title
NCT03919071	—	P2	active not recruiting	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
NCT03434262	SJDAWN	P1	completed	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Diffuse Astrocytoma (2)

NCT	Acronym	Phase	Status	Title
NCT03975829	—	P4	active not recruiting	Pediatric Long-Term Follow-up and Rollover Study
NCT02684058	—	P2	completed	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

KRAS Gene Mutation (2)

NCT	Acronym	Phase	Status	Title
NCT02642042	—	P2	active not recruiting	Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
NCT03299088	—	P1	completed	Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

Metastatic Malignant Neoplasm in the Brain (2)

NCT	Acronym	Phase	Status	Title
NCT02910700	—	P2	active not recruiting	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
NCT02015117	—	P1	active not recruiting	Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

Clinical Stage III Cutaneous Melanoma AJCC v8 (2)

NCT	Acronym	Phase	Status	Title
NCT01989585	—	P1/P2	active not recruiting	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
NCT02224781	—	P3	active not recruiting	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Recurrent Melanoma (2)

NCT	Acronym	Phase	Status	Title
NCT02296112	—	P2	completed	Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
NCT01701037	—	P2	terminated	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Advanced Malignancy (2)

NCT	Acronym	Phase	Status	Title
NCT02110355	—	P1	completed	A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
NCT02016729	—	P1	completed	A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

BRAF V600E Mutation Present (2)

NCT	Acronym	Phase	Status	Title
NCT02097225	—	P1	terminated	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT01940809	—	P1	terminated	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Melanoma and Brain Metastases (2)

NCT	Acronym	Phase	Status	Title
NCT02039947	—	P2	completed	Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
NCT01978236	—	P2	terminated	Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07468071	KontRASt-R	P1/P2	recruiting	Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Osteosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT07477457	—	P2	recruiting	A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Haematological Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT07440290	DETERMINE	P2/P3	not yet recruiting	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

BRAF V600 Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT07110246	PNOC037	P2	recruiting	Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Ras/MAPK Pathway Vascular Anomalies (1)

NCT	Acronym	Phase	Status	Title
NCT07549646	VATCH	P2	active not recruiting	24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

Vascular Anomalies (1)

NCT	Acronym	Phase	Status	Title
NCT07072403	—	P1/P2	active not recruiting	Trametinib Treatment for Complicated Vascular Anomalies

Thyroid Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT07010393	—	P4	not yet recruiting	Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Langerhans Cell Histiocytosis (LCH) (1)

NCT	Acronym	Phase	Status	Title
NCT07022834	—	P2	recruiting	Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children

Solid Tumor Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06962254	—	P1	recruiting	Imatinib and Trametinib for KRAS-mutated Solid Tumor

Low Grade Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT06712875	—	P1/P2	recruiting	MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Rare Malignant Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT06119789	MATRIX-Rare	P2	recruiting	Precision Cancer Therapy in Rare Cancers

Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT06967155	—	P2	active not recruiting	A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer

Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT06739395	—	P2	recruiting	Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Lung Cancer Stage III (1)

NCT	Acronym	Phase	Status	Title
NCT06563999	NUMER	P2	recruiting	Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Leukemia, Juvenile Myelomonocytic (1)

NCT	Acronym	Phase	Status	Title
NCT05849662	—	P1/P2	recruiting	A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Refractory Differentiated Thyroid Gland Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06475989	—	P3	recruiting	Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

NSCLC Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT06532149	EROS	N/A	recruiting	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Cardiomegaly (1)

NCT	Acronym	Phase	Status	Title
NCT06555237	MEKinRAS	P2	recruiting	MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies

Langerhans Cell Histiocytosis (1)

NCT	Acronym	Phase	Status	Title
NCT06582745	LCH	P2	recruiting	Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

Advanced or Metastatic NRAS-mutant Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT06346067	ERAS-254	P3	active not recruiting	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Arteriovenous Malformations (1)

NCT	Acronym	Phase	Status	Title
NCT06098872	—	P2	withdrawn	Pilot Study on Trametinib for Surgical Unruptured AVMs

Acute Lymphoblastic Leukemia, in Relapse (1)

NCT	Acronym	Phase	Status	Title
NCT05658640	HEM-iSMART D	P1/P2	recruiting	HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

Craniopharyngioma (1)

NCT	Acronym	Phase	Status	Title
NCT05525273	Swecranio	P2	recruiting	Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05874414	—	P1/P2	recruiting	Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Advanced or Metastatic Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT05907304	SEACRAFT-1	P1	active not recruiting	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Pancreatic Ductal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05440942	—	P1	completed	Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Advanced Uveal Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT05677373	—	P1/P2	withdrawn	Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Gastric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04454476	—	P1	active not recruiting	Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

KRAS G12C Mutant Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT05358249	KontRASt-03	P1/P2	active not recruiting	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Grade 1 Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT05180825	PLGG - MEKTRIC	P2	recruiting	Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

Bile Duct Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04566133	HCQ	P2	terminated	Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Differentiated Thyroid Cancer (DTC) (1)

NCT	Acronym	Phase	Status	Title
NCT04940052	—	P3	active not recruiting	Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Rosacea, Erythematotelangiectatic (1)

NCT	Acronym	Phase	Status	Title
NCT05616923	TOMIR	P1	completed	Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

Advanced Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT05048134	—	P1	terminated	A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Melanoma Stage III (1)

NCT	Acronym	Phase	Status	Title
NCT05171374	RATIONALE	N/A	unknown	pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE

Locally Advanced Thyroid Gland Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06482086	—	P2	recruiting	Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Histiocytosis (1)

NCT	Acronym	Phase	Status	Title
NCT04943224	TRAM	P2	recruiting	Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

Solid Tumor, Adult (1)

NCT	Acronym	Phase	Status	Title
NCT04803318	—	P2	recruiting	Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Recurrent World Health Organization (WHO) Grade II Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT04485559	PNOC021	P1	recruiting	Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Venous Malformation (1)

NCT	Acronym	Phase	Status	Title
NCT04258046	—	P2	completed	Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

BRAF NP_004324.2:p.V600E (1)

NCT	Acronym	Phase	Status	Title
NCT03975231	—	P1	recruiting	Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Carcinoma, Non-Small-Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT04452877	—	P2	completed	A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

BRAF V600 Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04294160	—	P1	terminated	A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Recurrent Acute Myeloid Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT04487106	—	P2	completed	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Amyotrophic Lateral Sclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT04326283	SNR1611	P1/P2	terminated	Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCT	Acronym	Phase	Status	Title
NCT03878524	SMMART	P1	terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT04310397	—	P2	terminated	Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Malignant Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04116541	MegaMOST	P2	recruiting	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Low Grade Glioma (LGG) of Brain With BRAF Aberration (1)

NCT	Acronym	Phase	Status	Title
NCT04201457	—	P1/P2	active not recruiting	A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Advanced Thyroid Cancer Patients Who Received Target Therapy (1)

NCT	Acronym	Phase	Status	Title
NCT06195228	—	P4	recruiting	A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Solid Tumors, KRAS Mutation; SOS1 (1)

NCT	Acronym	Phase	Status	Title
NCT04111458	—	P1	active not recruiting	A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Soft Tissue Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT03784014	MULTISARC	P3	completed	Molecular Profiling of Advanced Soft-tissue Sarcomas

Metastatic NRAS Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT03979651	CHLOROTRAMMEL	N/A	completed	MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma

Meningioma (1)

NCT	Acronym	Phase	Status	Title
NCT03631953	ALTREM	P1	recruiting	Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas

Melanoma (Skin) (1)

NCT	Acronym	Phase	Status	Title
NCT03972046	—	P2	withdrawn	Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Neurofibromatosis 1 (1)

NCT	Acronym	Phase	Status	Title
NCT03741101	plexifpc	P2	unknown	Treatment of NF1-related Plexiform Neurofibroma With Trametinib

Metastatic Pancreatic Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03825289	THREAD	P1	terminated	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

Stage IV Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04059224	TraMel-WT	P2	completed	TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

Erdheim-Chester Disease (1)

NCT	Acronym	Phase	Status	Title
NCT03794297	—	P2	withdrawn	Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03668431	—	P2	unknown	Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Juvenile Myelomonocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT03190915	—	P2	active not recruiting	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Non-Small-Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02672358	—	P2	withdrawn	Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Low-grade Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT03363217	—	P2	active not recruiting	Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Bronchial Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT03516214	EATON	P1	completed	EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Metastatic Colon Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03317119	—	P1	completed	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Malignant Neoplasms of Digestive Organs (1)

NCT	Acronym	Phase	Status	Title
NCT03428126	MEDI4736	P2	completed	Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

Metastatic Thyroid Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04619316	ERRITI	P2	unknown	Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

Hormone-Resistant Prostate Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02881242	—	P2	active not recruiting	Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

EGFR-mutant Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03333343	—	P1	active not recruiting	Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

EGFR NP_005219.2:p.S492R (1)

NCT	Acronym	Phase	Status	Title
NCT03087071	—	P2	active not recruiting	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT03244956	MERAIODE	P2	completed	Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Locally Advanced Epithelioid Hemangioendothelioma (1)

NCT	Acronym	Phase	Status	Title
NCT03148275	—	P2	completed	Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

Lung Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03076164	—	P1/P2	completed	A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Gastrointestinal Stromal Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT02342600	SARC029	P2	withdrawn	SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Solid Tumors for Phase Ib (1)

NCT	Acronym	Phase	Status	Title
NCT02703571	—	P1	terminated	Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Lymphoma, Non-Hodgkin (1)

NCT	Acronym	Phase	Status	Title
NCT02693535	TAPUR	P2	recruiting	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02258607	NSCLC	P1	terminated	Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Malignant Melanoma Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT02439411	DEIS	N/A	completed	Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain

Hepatocellular Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02292173	—	P1	completed	Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

BRAF V600E Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT02281760	—	P2	completed	Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

Advanced BRAF Mutant Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT02257424	BAMM	P1/P2	completed	Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Stage IIIB Cutaneous Melanoma AJCC v7 (1)

NCT	Acronym	Phase	Status	Title
NCT02231775	—	P2	active not recruiting	Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Prostate Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01990196	—	P2	active not recruiting	Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Stage III Cutaneous Melanoma AJCC v7 (1)

NCT	Acronym	Phase	Status	Title
NCT02196181	—	P2	active not recruiting	Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

Metastatic Thyroid Gland Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02152995	—	P2	active not recruiting	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Borderline Ovarian Serous Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT02101788	—	P2/P3	completed	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Metastatic Malignant Solid Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT02079740	—	P1/P2	active not recruiting	Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Adult Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02042443	S1310	P2	completed	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

Recurrent Uveal Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT01979523	—	P2	active not recruiting	Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

Cervical Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01958112	—	P2	terminated	GSK1120212+GSK2141795 for Cervical Cancer

Recurrent Adult Acute Myeloid Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT01907815	—	P2	terminated	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

Lung Cancer, Non-Small Cell (1)

NCT	Acronym	Phase	Status	Title
NCT01938456	—	P1	withdrawn	Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer

Recurrent Plasma Cell Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT01989598	—	P2	completed	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Recurrent Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT01912625	—	P1	terminated	Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Hematopoietic and Lymphoid Cell Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT01902173	—	P1/P2	completed	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Estrogen Receptor Negative (1)

NCT	Acronym	Phase	Status	Title
NCT01964924	—	P2	completed	Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Endometrial Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT01935973	—	P1	completed	Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

BRAFV600E Melanoma Patients (1)

NCT	Acronym	Phase	Status	Title
NCT01721603	—	P2	terminated	Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

Stage III Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT01726738	LCCC 1128	P2	completed	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Recurrent Rectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01740648	—	P1	completed	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer

Follicular Thyroid Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01723202	—	P2	completed	Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

Progressive Metastatic Castrate Resistant Prostate Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03386071	—	N/A	no longer available	Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Trametinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
ERAS-254	NCT06346067	P3	active not recruiting	Advanced or Metastatic NRAS-mutant Melanoma	78	—
MULTISARC	NCT03784014	P3	completed	Soft Tissue Sarcoma	603	PMID 34740331
COMBI-i	NCT02967692	P3	terminated	Melanoma	568	PMID 35728875
COMBI-AD	NCT01682083	P3	completed	Melanoma	870	PMID 40250457
COMBI-APlus	NCT03551626	P3	completed	Malignant Melanoma	552	PMID 35042070
COMBI-v	NCT01597908	P3	completed	Melanoma	704	PMID 34225229
LCH	NCT06582745	P2	recruiting	Langerhans Cell Histiocytosis	75	PMID 33089615
MATRIX-Rare	NCT06119789	P2	recruiting	Rare Malignant Neoplasm	96	—
PNOC037	NCT07110246	P2	recruiting	BRAF V600 Mutation	96	—
PLGG - MEKTRIC	NCT05180825	P2	recruiting	Grade 1 Glioma	134	—
VATCH	NCT07549646	P2	active not recruiting	Ras/MAPK Pathway Vascular Anomalies	45	—
NETCAM	NCT06653517	P2	recruiting	Ameloblastoma	12	—
NUMER	NCT06563999	P2	recruiting	Lung Cancer Stage III	120	—
TAPUR	NCT02693535	P2	recruiting	Lymphoma, Non-Hodgkin	4,200	PMID 36753688
MEMBRAINS	NCT03563729	P2	recruiting	Malignant Melanoma	80	—
Swecranio	NCT05525273	P2	recruiting	Craniopharyngioma	25	—
NEO-ATACT	NCT06079333	P2	recruiting	Anaplastic Thyroid Cancer	20	—
DRUP	NCT02925234	P2	recruiting	Cancer	1,550	PMID 37424386
MegaMOST	NCT04116541	P2	recruiting	Malignant Solid Tumor	455	—
TRAM	NCT04943224	P2	recruiting	Histiocytosis	12	PMID 26940938
MEKinRAS	NCT06555237	P2	recruiting	Cardiomegaly	40	PMID 40041314
FINPROVE	NCT05159245	P2	recruiting	Advanced Cancer	250	—
Neo Combi	NCT01972347	P2	active not recruiting	Melanoma	35	PMID 31171444
Match Mel	NCT02645149	P2	completed	Melanoma	216	PMID 34376578
PaTcH	NCT05518110	P2	terminated	Pancreatic Cancer	20	—
MERAIODE	NCT03244956	P2	completed	Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation	40	PMID 37350119
I-FIRST	NCT05182931	P2	unknown	Thyroid Cancer	80	—
ERRITI	NCT04619316	P2	unknown	Metastatic Thyroid Cancer	70	—
plexifpc	NCT03741101	P2	unknown	Neurofibromatosis 1	15	—
Neo Trio	NCT02858921	P2	unknown	Melanoma	60	PMID 38907159
ANAPLAST-NEO	NCT04739566	P2	withdrawn	Thyroid Gland Anaplastic Carcinoma	0	—
TraMel-WT	NCT04059224	P2	completed	Stage IV Melanoma	45	PMID 25243813
HCQ	NCT04566133	P2	terminated	Bile Duct Cancer	2	—
MEDI4736	NCT03428126	P2	completed	Malignant Neoplasms of Digestive Organs	29	PMID 36007963
INTERIM	NCT03352947	P2	completed	Melanoma	79	—
LCCC 1128	NCT01726738	P2	completed	Stage III Melanoma	17	—
PK	NCT03266159	P2	withdrawn	Solid Tumours	0	—
NF1	NCT03232892	P2	terminated	Non-small Cell Lung Cancer	1	—
IMPemBra	NCT02625337	P2	unknown	Metastatic Melanoma	32	PMID 37479483
BOTTOM	NCT02410863	P2	terminated	Malignant Melanoma	10	—
S1310	NCT02042443	P2	completed	Adult Cholangiocarcinoma	53	—
SARC029	NCT02342600	P2	withdrawn	Gastrointestinal Stromal Tumors	0	—

Terminated and withdrawn Trametinib trials (52)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT04892017terminatedStudy of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
NCT06098872withdrawnPilot Study on Trametinib for Surgical Unruptured AVMs
NCT05518110terminatedPaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer
NCT03825289terminatedTrametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
NCT05677373withdrawnTesting the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
NCT04294160terminatedA Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
NCT02967692terminatedA Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
NCT05435846terminatedCapmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
NCT02974725terminatedA Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
NCT04527549terminatedTesting Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
NCT04739566withdrawnDabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer
NCT04310397terminatedDabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
NCT05048134terminatedA Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
NCT04326283terminatedTrial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT05299580withdrawn"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
NCT05071183terminatedA Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
NCT01912625terminatedTrametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT04566133terminatedCombination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
NCT04801966terminatedSafety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
NCT02097225terminatedOnalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT03087448terminatedCeritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT01940809terminatedIpilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
NCT03794297withdrawnDabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
NCT03878524terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
NCT02672358withdrawnStudy of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
NCT03266159withdrawnA Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors
NCT02974803terminatedConcurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
NCT03972046withdrawnNeoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
NCT03272464terminatedINCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
NCT02703571terminatedStudy of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
NCT03232892terminatedTrametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
NCT02447939withdrawnPharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
NCT02939846withdrawnPharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
NCT03580382terminatedStudy of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
NCT02410863terminatedBiopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
NCT01958112terminatedGSK1120212+GSK2141795 for Cervical Cancer
NCT02143050withdrawnStudy of Dabrafenib, Trametinib and Metformin for Melanoma Patients
NCT02915666withdrawnA Clinical Trial of Patients With Melanoma
NCT02292732withdrawnA Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
NCT01978236terminatedDabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
NCT02258607terminatedEfficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase
NCT02342600withdrawnSARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
NCT02314143terminatedPhase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
NCT02538627terminatedPhase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
NCT02580708terminatedPhase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
NCT02140840withdrawnUARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib
NCT01907815terminatedTrametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
NCT01721603terminatedDabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
NCT02300935withdrawnStudy of Trametinib and Nab-paclitaxel in Patients With Melanoma
NCT02357732withdrawnStudy of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
NCT01701037terminatedDabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
NCT01938456withdrawnSafety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer

All Trametinib trials (243)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06582745	LCH	Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib	P2	recruiting	75	Cook Children's Health Care System	Jun 2024
NCT04803318		Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors	P2	recruiting	100	Second Affiliated Hospital of Guangzhou Medical University	Jan 2021
NCT06119789	MATRIX-Rare	Precision Cancer Therapy in Rare Cancers	P2	recruiting	96	Oslo University Hospital	Mar 2025
NCT03340506		Dabrafenib and/or Trametinib Rollover Study	P4	recruiting	100	Novartis Pharmaceuticals	Dec 2017
NCT07092670	MELAFERT	MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.	—	recruiting	270	Intergruppo Melanoma Italiano	Aug 2025
NCT07110246	PNOC037	Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas	P2	recruiting	96	University of California, San Francisco	Nov 2025
NCT05180825	PLGG - MEKTRIC	Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy	P2	recruiting	134	University Hospital, Strasbourg, France	May 2022
NCT06475989		Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer	P3	recruiting	264	ECOG-ACRIN Cancer Research Group	Aug 2024
NCT07549646	VATCH	24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs	P2	active not recruiting	45	Children's Hospital of Philadelphia	Aug 2025
NCT07022834		Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children	P2	recruiting	20	West China Second University Hospital	Jun 2025
NCT04903119		Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma	P1	recruiting	30	Rina Plattner	Jun 2022
NCT05849662		A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia	P1/P2	recruiting	58	Therapeutic Advances in Childhood Leukemia Consortium	Oct 2024
NCT06653517	NETCAM	Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma	P2	recruiting	12	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	Jan 2023
NCT06563999	NUMER	Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.	P2	recruiting	120	Sun Yat-sen University	Nov 2024
NCT07440290	DETERMINE	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.	P2/P3	not yet recruiting	30	Cancer Research UK	Feb 2026
NCT07468071	KontRASt-R	Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments	P1/P2	recruiting	40	Novartis Pharmaceuticals	Jun 2026
NCT03899155		Pan Tumor Rollover Study	P2	recruiting	1,500	Bristol-Myers Squibb	Aug 2019
NCT07419932	NeoLATC	Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer	—	recruiting	120	Fujian Medical University	Dec 2025
NCT06712875		MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas	P1/P2	recruiting	27	Ann & Robert H Lurie Children's Hospital of Chicago	Apr 2025
NCT05658640	HEM-iSMART D	HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	P1/P2	recruiting	26	Princess Maxima Center for Pediatric Oncology	Nov 2023
NCT07010393		Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study	P4	not yet recruiting	335	Fujian Medical University	Jul 2025
NCT06819605	NETCAM-RCT	Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma	P2/P3	not yet recruiting	46	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	Mar 2025
NCT06456138		Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC	P1/P2	not yet recruiting	60	Shanghai Chest Hospital	Jul 2024
NCT06346067	ERAS-254	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)	P3	active not recruiting	78	Erasca, Inc.	Apr 2024
NCT06195228		A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer	P4	recruiting	800	Fudan University	Jan 2020
NCT02693535	TAPUR	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	P2	recruiting	4,200	American Society of Clinical Oncology	Mar 2016
NCT05275374	ENHANCE	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	P1/P2	not yet recruiting	221	Xynomic Pharmaceuticals, Inc.	Dec 2025
NCT03065387		Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	P1	active not recruiting	93	M.D. Anderson Cancer Center	Oct 2017
NCT06967155		A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer	P2	active not recruiting	23	Blokhin's Russian Cancer Research Center	Mar 2025
NCT03563729	MEMBRAINS	Melanoma Metastasized to the Brain and Steroids	P2	recruiting	80	Inge Marie Svane	Jun 2018
NCT05525273	Swecranio	Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma	P2	recruiting	25	Eva Marie Erfurth, MD, PhD	Sep 2023
NCT06962254		Imatinib and Trametinib for KRAS-mutated Solid Tumor	P1	recruiting	10	China Medical University Hospital	May 2025
NCT07477457		A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma	P2	recruiting	45	Memorial Sloan Kettering Cancer Center	Mar 2026
NCT04666272		Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection	—	active not recruiting	78	Novartis Pharmaceuticals	Dec 2020
NCT06079333	NEO-ATACT	NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)	P2	recruiting	20	Leiden University Medical Center	Jan 2023
NCT04485559	PNOC021	Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)	P1	recruiting	50	University of California, San Francisco	Dec 2020
NCT04111458		A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)	P1	active not recruiting	71	Boehringer Ingelheim	Nov 2019
NCT03225664		Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced	P1/P2	active not recruiting	37	M.D. Anderson Cancer Center	Feb 2018
NCT02925234	DRUP	The Drug Rediscovery Protocol (DRUP Trial)	P2	recruiting	1,550	The Netherlands Cancer Institute	Aug 2016
NCT01989585		Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	P1/P2	active not recruiting	75	National Cancer Institute (NCI)	Mar 2014
NCT02910700		Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma	P2	active not recruiting	52	M.D. Anderson Cancer Center	Dec 2016
NCT04185883		Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	P1	active not recruiting	610	Amgen	Dec 2019
NCT04116541	MegaMOST	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.	P2	recruiting	455	Centre Leon Berard	Jan 2020
NCT03975231		Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	P1	recruiting	6	City of Hope Medical Center	Sep 2020
NCT03919071		Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	P2	active not recruiting	58	National Cancer Institute (NCI)	Feb 2020
NCT07072403		Trametinib Treatment for Complicated Vascular Anomalies	P1/P2	active not recruiting	20	West China Hospital	Jul 2025
NCT06804824	FIH	A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors	P1	recruiting	220	Vividion Therapeutics, Inc.	Feb 2025
NCT04943224	TRAM	Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients	P2	recruiting	12	Anna Raciborska	Apr 2021
NCT04940052		Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer	P3	active not recruiting	153	Novartis Pharmaceuticals	Nov 2021
NCT06739395		Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion	P2	recruiting	300	Tianjin Medical University Second Hospital	Nov 2024
NCT05988697		Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib	—	not yet recruiting	36	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	Nov 2023
NCT02231775		Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation	P2	active not recruiting	58	M.D. Anderson Cancer Center	Oct 2014
NCT04439279		Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	P2	active not recruiting	35	National Cancer Institute (NCI)	Aug 2015
NCT02196181		Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread	P2	active not recruiting	280	National Cancer Institute (NCI)	Sep 2014
NCT04557956		Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	P1/P2	active not recruiting	16	National Cancer Institute (NCI)	Aug 2021
NCT02079740		Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	P1/P2	active not recruiting	96	National Cancer Institute (NCI)	Mar 2014
NCT02642042		Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer	P2	active not recruiting	60	National Cancer Institute (NCI)	Jul 2016
NCT06054191		Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations	P2	not yet recruiting	40	Sun Yat-sen University	Feb 2024
NCT03363217		Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.	P2	active not recruiting	114	St. Justine's Hospital	Aug 2018
NCT02152995		Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	P2	active not recruiting	34	National Cancer Institute (NCI)	Aug 2014
NCT04417621		Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma	P2	active not recruiting	134	Novartis Pharmaceuticals	Oct 2020
NCT03087071		Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	P2	active not recruiting	59	M.D. Anderson Cancer Center	Dec 2017
NCT04439357		Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)	P2	active not recruiting	4	National Cancer Institute (NCI)	Feb 2016
NCT05907304	SEACRAFT-1	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations	P1	active not recruiting	86	Erasca, Inc.	Aug 2023
NCT03149029		Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma	P2	active not recruiting	16	Massachusetts General Hospital	Nov 2017
NCT04439318		Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)	P2	active not recruiting	50	National Cancer Institute (NCI)	Feb 2016
NCT04439292		Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	P2	active not recruiting	44	National Cancer Institute (NCI)	Jan 2016
NCT02465060		Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	P2	active not recruiting	6,452	National Cancer Institute (NCI)	Aug 2015
NCT02224781		Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	P3	active not recruiting	267	National Cancer Institute (NCI)	Sep 2015
NCT06555237	MEKinRAS	MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies	P2	recruiting	40	Medical University of Warsaw	Aug 2024
NCT05159245	FINPROVE	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs	P2	recruiting	250	Helsinki University Central Hospital	Dec 2021
NCT03975829		Pediatric Long-Term Follow-up and Rollover Study	P4	active not recruiting	165	Novartis Pharmaceuticals	Nov 2019
NCT05874414		Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma	P1/P2	recruiting	74	Genfit	Aug 2023
NCT04675710		Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer	P2	active not recruiting	30	M.D. Anderson Cancer Center	Jun 2021
NCT05372354	BMS-986348	A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma	P1/P2	recruiting	260	Bristol-Myers Squibb	Oct 2022
NCT02015117		Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases	P1	active not recruiting	10	National Cancer Institute (NCI)	Apr 2014
NCT03333343		Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC	P1	active not recruiting	105	Novartis Pharmaceuticals	Jan 2018
NCT03190915		Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	P2	active not recruiting	10	National Cancer Institute (NCI)	Sep 2018
NCT06532149	EROS	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer	—	recruiting	80	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Aug 2024
NCT05358249	KontRASt-03	Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	P1/P2	active not recruiting	74	Novartis Pharmaceuticals	Oct 2022
NCT03085056		Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer	Early P1	active not recruiting	13	Memorial Sloan Kettering Cancer Center	Mar 2017
NCT01990196		Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer	P2	active not recruiting	45	Jonsson Comprehensive Cancer Center	Sep 2014
NCT03091257		A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	P1	active not recruiting	30	Massachusetts General Hospital	Jun 2017
NCT04544111		PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	P2	active not recruiting	19	Memorial Sloan Kettering Cancer Center	Sep 2020
NCT01979523		Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma	P2	active not recruiting	42	National Cancer Institute (NCI)	Nov 2013
NCT06362694		Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy	P2	recruiting	10	Saint Petersburg State University, Russia	Mar 2024
NCT04238624		Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	P2	active not recruiting	16	Memorial Sloan Kettering Cancer Center	Jan 2020
NCT01972347	Neo Combi	Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma	P2	active not recruiting	35	Melanoma Institute Australia	Oct 2014
NCT05876806		Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations	P2	unknown	30	Se Jun Park	Jun 2023
NCT04201457		A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration	P1/P2	active not recruiting	57	Pediatric Brain Tumor Consortium	Jan 2020
NCT04892017	DCC-3116	Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors	P1	terminated	91	Deciphera Pharmaceuticals, LLC	Jun 2021
NCT06098872		Pilot Study on Trametinib for Surgical Unruptured AVMs	P2	withdrawn	0	University Health Network, Toronto	Jan 2024
NCT02645149	Match Mel	Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma	P2	completed	216	Melanoma Institute Australia	Nov 2021
NCT05518110	PaTcH	PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer	P2	terminated	20	Cancer Trials Ireland	May 2023
NCT04258046		Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation	P2	completed	25	Stanford University	Dec 2020
NCT03631953	ALTREM	Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas	P1	recruiting	25	Assistance Publique Hopitaux De Marseille	Sep 2019
NCT03784014	MULTISARC	Molecular Profiling of Advanced Soft-tissue Sarcomas	P3	completed	603	Institut National de la Santé Et de la Recherche Médicale, France	Oct 2019
NCT03244956	MERAIODE	Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer	P2	completed	40	Gustave Roussy, Cancer Campus, Grand Paris	Dec 2017
NCT04454476		Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor	P1	active not recruiting	15	Vanderbilt-Ingram Cancer Center	Nov 2022
NCT05182931	I-FIRST	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)	P2	unknown	80	Olivia Newton-John Cancer Research Institute	Jul 2022
NCT06482086		Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer	P2	recruiting	75	West China Hospital	Jun 2021
NCT05668585		A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors	P1	completed	89	C4 Therapeutics, Inc.	Dec 2022
NCT02101788		Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	P2/P3	completed	260	National Cancer Institute (NCI)	Apr 2014
NCT03825289	THREAD	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer	P1	terminated	25	University of Utah	Jan 2019
NCT05677373		Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma	P1/P2	withdrawn	0	Alliance for Clinical Trials in Oncology	Jan 2023
NCT05440942		Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma	P1	completed	28	Peter Hosein, MD	Jan 2023
NCT02881242		Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer	P2	active not recruiting	14	Jonsson Comprehensive Cancer Center	Jan 2018
NCT03026517		Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma	P1	completed	18	Memorial Sloan Kettering Cancer Center	Jan 2017
NCT04619316	ERRITI	Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition	P2	unknown	70	University Hospital, Essen	Feb 2018
NCT03501368		Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma	P1	completed	27	H. Lee Moffitt Cancer Center and Research Institute	Jun 2018
NCT02070549		Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction	P1	completed	46	National Cancer Institute (NCI)	Mar 2014
NCT03741101	plexifpc	Treatment of NF1-related Plexiform Neurofibroma With Trametinib	P2	unknown	15	Region Skane	Jun 2019
NCT04961619	LEAD Melanoma	Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.	—	completed	39	Novartis Pharmaceuticals	Dec 2021
NCT02858921	Neo Trio	Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	P2	unknown	60	Melanoma Institute Australia	Nov 2017
NCT04452877		A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC	P2	completed	40	Novartis Pharmaceuticals	Aug 2020
NCT03377361	CheckMate 9N9	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread	P1/P2	completed	325	Bristol-Myers Squibb	Jan 2018
NCT03944356	Combi-EU	BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	—	completed	232	EuMelaReg gGmbH	Jul 2019
NCT05171374	RATIONALE	pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE	—	unknown	500	MelanomaPRO, Russia	Sep 2021
NCT04294160		A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer	P1	terminated	122	Novartis Pharmaceuticals	Jul 2020
NCT02967692	COMBI-i	A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma	P3	terminated	568	Novartis Pharmaceuticals	Feb 2017
NCT03299088		Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations	P1	completed	15	Jonathan Riess	Jun 2018
NCT05435846		Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	P1	terminated	3	Collin Blakely	Aug 2022
NCT03434262	SJDAWN	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	P1	completed	68	St. Jude Children's Research Hospital	Mar 2018
NCT02872259		BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma	P1/P2	completed	74	Haukeland University Hospital	Feb 2017
NCT02974725		A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	P1	terminated	241	Novartis Pharmaceuticals	Feb 2017
NCT04303403		Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma	P1	unknown	48	National Cancer Centre, Singapore	Jul 2018
NCT04967079		Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients	P1	completed	33	Shanghai Chest Hospital	Aug 2021
NCT04487106		Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	P2	completed	21	M.D. Anderson Cancer Center	Jul 2020
NCT04527549		Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	P2	terminated	5	ECOG-ACRIN Cancer Research Group	Jun 2021
NCT05260684	OCEANMIST	Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US	—	completed	716	Pfizer	Jan 2022
NCT01902173		Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	P1/P2	completed	27	National Cancer Institute (NCI)	Oct 2013
NCT04739566	ANAPLAST-NEO	Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer	P2	withdrawn	0	Saint Petersburg State University, Russia	Jan 2021
NCT03516214	EATON	EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations	P1	completed	18	University of Cologne	Apr 2018
NCT04310397		Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma	P2	terminated	4	M.D. Anderson Cancer Center	Jan 2020
NCT03714958	TRAHD	Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type	P1	completed	12	Centre Leon Berard	Dec 2018
NCT03455764		MCS110 With BRAF/MEK Inhibition in Patients With Melanoma	P1/P2	completed	6	Dana-Farber Cancer Institute	Sep 2018
NCT01682083	COMBI-AD	Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).	P3	completed	870	Novartis Pharmaceuticals	Jan 2013
NCT03317119		Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	P1	completed	26	City of Hope Medical Center	Apr 2018
NCT04059224	TraMel-WT	TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma	P2	completed	45	Universitair Ziekenhuis Brussel	Jan 2019
NCT03148275		Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery	P2	completed	44	National Cancer Institute (NCI)	Jun 2017
NCT05048134		A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies	P1	terminated	13	Jiangsu HengRui Medicine Co., Ltd.	Oct 2021
NCT04326283	SNR1611	Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)	P1/P2	terminated	23	Genuv Inc.	Apr 2020
NCT02684058		Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors	P2	completed	151	Novartis Pharmaceuticals	Dec 2017
NCT05299580		"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"	P2	withdrawn	0	Fondazione Melanoma Onlus	Feb 2021
NCT05071183		A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors	P1/P2	terminated	9	Turning Point Therapeutics, Inc.	Sep 2021
NCT01912625		Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	P1	terminated	16	National Cancer Institute (NCI)	Oct 2013
NCT03979651	CHLOROTRAMMEL	MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma	N/A	completed	29	Hospices Civils de Lyon	Oct 2019
NCT04566133	HCQ	Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).	P2	terminated	2	National Cancer Institute (NCI)	Feb 2022
NCT05616923	TOMIR	Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea	P1	completed	12	Albany Research Institute, Inc.	Nov 2021
NCT04801966	TAILOR	Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study	N/A	terminated	3	Peter MacCallum Cancer Centre, Australia	Sep 2021
NCT03668431		Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	P2	unknown	25	Massachusetts General Hospital	Oct 2018
NCT02428270		A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer	P2	completed	16	University Health Network, Toronto	Apr 2016
NCT02097225		Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	P1	terminated	22	National Cancer Institute (NCI)	May 2014
NCT03754179	COMBI-R2	Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma	P1/P2	unknown	63	Universitair Ziekenhuis Brussel	Jan 2018
NCT03543306		Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation	P2	unknown	27	Asan Medical Center	Jun 2018
NCT04547946		Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)	—	completed	3	Novartis Pharmaceuticals	Oct 2021
NCT03428126	MEDI4736	Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer	P2	completed	29	M.D. Anderson Cancer Center	Mar 2018
NCT04554680		Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy	P2	unknown	5	National University Hospital, Singapore	Dec 2020
NCT03087448	NSCLC	Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	P1	terminated	9	University of California, San Francisco	Sep 2017
NCT01723202		Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer	P2	completed	53	Bhavana Konda	Nov 2012
NCT02399943		A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer	P2	completed	14	University Health Network, Toronto	Jun 2015
NCT01940809		Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	P1	terminated	15	National Cancer Institute (NCI)	Aug 2013
NCT03704688		Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer	P1/P2	completed	12	Memorial Sloan Kettering Cancer Center	Oct 2018
NCT05714371		Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma	—	completed	618	Novartis Pharmaceuticals	Oct 2021
NCT02034110		Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers	P2	completed	206	Novartis Pharmaceuticals	Mar 2014
NCT05611229		Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden	—	completed	1,975	Novartis Pharmaceuticals	Jun 2020
NCT02257424	BAMM	Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma	P1/P2	completed	50	Abramson Cancer Center at Penn Medicine	Oct 2014
NCT01827384		MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations	P2	completed	208	National Cancer Institute (NCI)	Jan 2014
NCT01740648		Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	P1	completed	19	Ohio State University Comprehensive Cancer Center	Nov 2012
NCT03551626	COMBI-APlus	Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes	P3	completed	552	Novartis Pharmaceuticals	Aug 2018
NCT02130466	MK-3475	A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)	P1/P2	completed	184	Merck Sharp & Dohme LLC	May 2014
NCT03088176		Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma	P1	unknown	4	West Cancer Center	Jun 2017
NCT02083354		Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma	P2	completed	77	Novartis Pharmaceuticals	Mar 2014
NCT02296112		Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations	P2	completed	9	Vanderbilt-Ingram Cancer Center	Jan 2015
NCT03794297		Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations	P2	withdrawn	0	National Cancer Institute (NCI)	Jan 2019
NCT02292173		Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer	P1	completed	17	H. Lee Moffitt Cancer Center and Research Institute	Feb 2015
NCT01336634		Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.	P2	completed	177	Novartis Pharmaceuticals	Aug 2011
NCT02124772	PK	Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations	P1/P2	completed	139	Novartis Pharmaceuticals	Jan 2015
NCT03076164		A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	P1/P2	completed	24	Memorial Sloan Kettering Cancer Center	Mar 2017
NCT03878524	SMMART	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	P1	terminated	2	OHSU Knight Cancer Institute	Apr 2020
NCT02672358		Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC	P2	withdrawn	0	Novartis Pharmaceuticals	Sep 2018
NCT03352947	INTERIM	Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma	P2	completed	79	Cambridge University Hospitals NHS Foundation Trust	Nov 2017
NCT01989598		Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma	P2	completed	25	National Cancer Institute (NCI)	Oct 2013
NCT01726738	LCCC 1128	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	P2	completed	17	UNC Lineberger Comprehensive Cancer Center	Apr 2013
NCT04544202		Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection	—	no longer available	0	Novartis Pharmaceuticals	—
NCT03266159	PK	A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors	P2	withdrawn	0	GlaxoSmithKline	Nov 2017
NCT02974803		Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	P2	terminated	6	Canadian Cancer Trials Group	Feb 2018
NCT04489433		Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma	—	no longer available	0	Novartis Pharmaceuticals	—
NCT01750918	CRC	BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)	P1/P2	completed	166	Novartis Pharmaceuticals	Dec 2012
NCT02392871	CombiRT	Radiotherapy & Combi in Metastatic Melanoma	P1/P2	completed	10	Melanoma and Skin Cancer Trials Limited	May 2015
NCT03972046		Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma	P2	withdrawn	0	TriHealth Inc.	Jun 2019
NCT03272464		INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.	P1	terminated	1	Massachusetts General Hospital	May 2019
NCT02703571		Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors	P1	terminated	95	Novartis Pharmaceuticals	Jun 2016
NCT03232892	NF1	Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer	P2	terminated	1	University of California, San Francisco	Feb 2018
NCT02705963		A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors	P1	completed	19	Novartis Pharmaceuticals	Oct 2016
NCT02230553	M14LTK	Lapatinib Plus Trametinib in KRAS Mutant NSCLC	P1/P2	completed	35	The Netherlands Cancer Institute	Oct 2014
NCT02367859		Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma	P2	completed	1	Stanford University	Jul 2017
NCT01597908	COMBI-v	Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma	P3	completed	704	Novartis Pharmaceuticals	Jun 2012
NCT01584648		A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma	P3	completed	423	Novartis Pharmaceuticals	May 2012
NCT02447939		Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma	P1	withdrawn	0	GlaxoSmithKline	May 2017
NCT02939846		Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours	P1	withdrawn	0	GlaxoSmithKline	May 2017
NCT02625337	IMPemBra	Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients	P2	unknown	32	The Netherlands Cancer Institute	Jan 2016
NCT02110355		A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma	P1	completed	31	Kartos Therapeutics, Inc.	Dec 2014
NCT03580382	WT	Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma	P1/P2	terminated	3	NYU Langone Health	Jul 2018
NCT02410863	BOTTOM	Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma	P2	terminated	10	Prof. Dr. med. Dirk Schadendorf	Nov 2015
NCT02281760		Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease	P2	completed	9	National Human Genome Research Institute (NHGRI)	Nov 2014
NCT02027961		Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone	P1	completed	68	MedImmune LLC	Dec 2013
NCT01964924		Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer	P2	completed	37	National Cancer Institute (NCI)	Oct 2013
NCT02039947		Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain	P2	completed	127	Novartis Pharmaceuticals	Feb 2014
NCT02296996		Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients	P2	completed	25	Universitair Ziekenhuis Brussel	Oct 2014
NCT03386071		Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib	—	no longer available	0	Jonsson Comprehensive Cancer Center	—
NCT01958112		GSK1120212+GSK2141795 for Cervical Cancer	P2	terminated	14	Dana-Farber Cancer Institute	Oct 2013
NCT02143050		Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients	P1/P2	withdrawn	0	University of Louisville	Sep 2014
NCT02016729		A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia	P1	completed	36	Kartos Therapeutics, Inc.	Apr 2014
NCT02915666		A Clinical Trial of Patients With Melanoma	P1	withdrawn	0	University of Texas Southwestern Medical Center	Oct 2016
NCT02292732	PK	A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors	P1	withdrawn	0	GlaxoSmithKline	Feb 2016
NCT01941927		Trametinib With GSK2141795 in BRAF Wild-type Melanoma	P2	completed	20	Adil Daud	Sep 2013
NCT02042443	S1310	Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery	P2	completed	53	National Cancer Institute (NCI)	Feb 2014
NCT01978236		Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites	P2	terminated	6	GlaxoSmithKline	Apr 2014
NCT02258607	NSCLC	Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase	P1	terminated	21	Sierra Oncology LLC - a GSK company	Mar 2015
NCT02138292		A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma	P1	completed	27	University of Texas Southwestern Medical Center	Jul 2014
NCT02342600	SARC029	SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)	P2	withdrawn	0	Sarcoma Alliance for Research through Collaboration	Jan 2017
NCT02314143		Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib	P2	terminated	48	GlaxoSmithKline	Nov 2013
NCT01287546		A Study of LY2875358 in Participants With Advanced Cancer	P1	completed	117	Eli Lilly and Company	Apr 2010
NCT02538627		Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib	P1	terminated	5	Merrimack Pharmaceuticals	Aug 2015
NCT02439411	DEIS	Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain	—	completed	135	Grupo Español Multidisciplinar de Melanoma	Mar 2015
NCT01928940		Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)	P2	completed	12	GlaxoSmithKline	Aug 2013
NCT02580708		Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer	P1/P2	terminated	7	Clovis Oncology, Inc.	Sep 2015
NCT02065063		A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors	P1	completed	28	GlaxoSmithKline	Apr 2014
NCT01938443		A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors	P1	completed	34	GlaxoSmithKline	Nov 2013
NCT02140840		UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib	P2	withdrawn	0	University of Arkansas	Mar 2015
NCT01943864		A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers	P2	completed	20	GlaxoSmithKline	Sep 2013
NCT01907815		Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia	P2	terminated	24	National Cancer Institute (NCI)	Oct 2013
NCT01721603		Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets	P2	terminated	2	University of California, San Francisco	Apr 2013
NCT02300935		Study of Trametinib and Nab-paclitaxel in Patients With Melanoma	P1	withdrawn	0	SCRI Development Innovations, LLC	Dec 2015
NCT01935973		Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	P1	completed	26	National Cancer Institute (NCI)	Sep 2013
NCT01767454		Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma	P1	completed	38	GlaxoSmithKline	Feb 2013
NCT02357732		Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib	P1	withdrawn	0	University of Pittsburgh	Aug 2015
NCT01701037		Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	P2	terminated	13	Vanderbilt-Ingram Cancer Center	Jan 2013
NCT02416232		Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma	—	no longer available	0	GlaxoSmithKline	—
NCT01938456		Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer	P1	withdrawn	0	GlaxoSmithKline	Oct 2013
NCT01192165		Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel	P1	completed	169	GlaxoSmithKline	Sep 2010
NCT01647659		Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation	P1	completed	18	GlaxoSmithKline	Jul 2012

Trametinib clinical trials: frequently asked questions

How many Trametinib clinical trials are there?: 243 Trametinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 40 are actively recruiting participants. 81 are marked completed.
Are Trametinib clinical trials recruiting in 2026?: Yes — 40 Trametinib trials are actively recruiting in 2026, with 519 U.S. sites across 45 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Trametinib being studied for?: Trametinib is being studied for Melanoma, Cancer, Metastatic Melanoma, Colorectal Cancer, Unresectable Melanoma and 537 more. The trials are grouped by indication on this page.
What phase is Trametinib in?: Trametinib clinical trials span 4 Phase 4, 10 Phase 3, 108 Phase 2, 64 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Trametinib clinical trials?: The lead sponsor across the most Trametinib trials is Novartis Pharmaceuticals, with 117 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Trametinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Trametinib overview Trametinib evidence & publications